BIOLOGICAL MODELING OF 5-FLUOROURACIL DEVELOPMENTAL TOXICITY

被引:32
作者
SHUEY, DL
SETZER, RW
LAU, C
ZUCKER, RM
ELSTEIN, KH
NAROTSKY, MG
KAVLOCK, RJ
ROGERS, JM
机构
[1] US EPA,HLTH EFFECTS RES LAB,RES TRIANGLE PK,NC 27711
[2] MANTECH ENVIRONM TECHNOL INC,RES TRIANGLE PK,NC 27709
关键词
5-FLUOROURACIL; 5-FU; MECHANISMS; MECHANISTIC MODELING; DEVELOPMENTAL TOXICITY; BIOLOGICALLY-BASED DOSE-RESPONSE;
D O I
10.1016/0300-483X(95)03049-L
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A biologically-based dose-response (BBDR) model is a mathematical description of the biological events leading to expression of a toxic response. As an alternative to current approaches in non-cancer risk assessment, such models will reduce uncertainty in that they will provide a more comprehensive description of toxicity. We are involved in construction of a BBDR model for the developmental toxicity of 5-fluorouracil (5-FU) in the rat using multiple approaches. First, to identify critical events in the pathogenesis of 5-FU developmental toxicity, thymidylate synthetase (TS) inhibition and alterations in cell cycle kinetics and growth were examined in embryos following maternal administration of 5-FU on day 14 of gestation. A dose-related decline in TS activity was observed within I h; however, maximal inhibition and recovery were similar at 10, 20 and 40 mg/kg. Dose-dependent cell cycle alterations were observed within 4 h after exposure and were maximal at 8 h. Hindlimb growth reduction was observed 24 h after exposure to 40 mg/kg, but not at lower doses. At term hindlimb defects were observed at doses above 30mg/kg. An integrated dose-response model for hindlimb defects was derived from empirical relationships among these events. The resultant dose-response somewhat over-predicted the developmental toxicity of 5-FU, although results of a Monte Carlo simulation indicated that these data were not incompatible with model predictions. Overall, the results suggest that TS inhibition is a key component of the mechanism of 5-FU developmental toxicology, but the model does not capture all of the critical events in the induction of hindlimb defects. A preliminary mechanistic model for the inhibition of embryonic TS, DNA synthesis and cell cycle following maternal exposure to 5-FU, independently derived from literature data to further examine the potential role of this pathway in its developmental toxicity, predicted a dose-response for TS inhibition and DNA synthesis that closely reflected the observed patterns. These results further suggest that TS inhibition, resultant deficits in DNA synthesis and cell cycle perturbations represent a critical mechanistic pathway in the developmental toxicity of 5-FU.
引用
收藏
页码:207 / 213
页数:7
相关论文
共 23 条
[1]  
ANDERSEN ME, 1992, CIIT ACTIVITIES, V12, P1
[2]   CHEMOTHERAPY IN A PREGNANT RAT MODEL .2. 5-FLUOROURACIL - NONLINEAR KINETICS AND PLACENTAL-TRANSFER [J].
BOIKE, GM ;
DEPPE, G ;
YOUNG, JD ;
MALONE, JM ;
MALVIYA, VK ;
SOKOL, RJ .
GYNECOLOGIC ONCOLOGY, 1989, 34 (02) :191-194
[3]  
CHAUBE S, 1968, ADV TERATOL, V3, P181
[4]   NON-LINEAR PHARMACOKINETIC MODELS FOR 5-FLUOROURACIL IN MAN - INTRAVENOUS AND INTRAPERITONEAL ROUTES [J].
COLLINS, JM ;
DEDRICK, RL ;
KING, FG ;
SPEYER, JL ;
MYERS, CE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (02) :235-246
[5]  
CONOLLY RB, 1991, ANNU REV PHARMACOL, V31, P503
[6]   SENSITIVE STAGES FOR THE PRODUCTION OF DEVELOPMENTAL ABNORMALITIES IN MICE WITH 5-FLUOROURACIL [J].
DAGG, CP .
AMERICAN JOURNAL OF ANATOMY, 1960, 106 (02) :89-96
[7]   FLUORINATED PYRIMIDINES AS TIGHT-BINDING INHIBITORS OF THYMIDYLATE SYNTHETASE [J].
DANENBERG, PV ;
LOCKSHIN, A .
PHARMACOLOGY & THERAPEUTICS, 1981, 13 (01) :69-90
[8]   EFFECTS OF DEVELOPMENTAL STAGE AND TISSUE-TYPE ON EMBRYO FETAL DNA DISTRIBUTIONS AND 5-FLUOROURACIL-INDUCED CELL-CYCLE PERTURBATIONS [J].
ELSTEIN, KH ;
ZUCKER, RM ;
ANDREWS, JE ;
EBRONMCCOY, M ;
SHUEY, DL ;
ROGERS, JM .
TERATOLOGY, 1993, 48 (04) :355-363
[9]   PROCESS OF BUILDING BIOLOGICALLY BASED DOSE-RESPONSE MODELS FOR DEVELOPMENTAL DEFECTS [J].
GAYLOR, DW ;
RAZZAGHI, M .
TERATOLOGY, 1992, 46 (06) :573-581
[10]   THE KINETIC-PROPERTIES OF SWITCH ANTIMETABOLITES [J].
JACKSON, RC .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (07) :539-545